Gannex, A Wholly Owned Company Of Ascletis Pharma, Announced The Positive Clinical Results In Overweight And Obese Subjects For Asc41, A Liver-Targeted Prodrug. The Active Metabolite Of Asc41 Is A Selective Thyroid Hormone Receptor Beta (Thr-&Szlig;) Agonist.Twenty Overweight And Obese Subjects With Elevated Low Density Lipoprotein Cholesterol (Ldl-C) (≫ 110 Mg/Dl) Were Treated With Asc41 10 Mg Oral Tablets Or Matching Placebo Tablets Once Daily In This Randomized, Double-Blind, Placebo Controlled Clinical Study. Preliminary Data Suggested That Over 28 Days Of Oral Dosing Of Asc41, Subjects Demonstrated Sustainable, Clinically Meaningful And Statistically Significant Reduction In Ldl-C, Triglyceride (Tg), Total Cholesterol (Tc), Compared To Placebo. High-Density Lipoprotein Cholesterol (Hdl-C) Remained Relatively Unchanged.Asc41 Had A Relatively Benign Adverse Event Profile In This Study. The Majority Of Adverse Events (Aes) Were Grade 1 Or 2, With Only 3 Grades 3 Aes (2 In The Asc41 Group And 1 In The Placebo Group). There Were No Serious Adverse Events (Saes).&Ldquo;We Are Excited About The Completion Of This Clinical Study In Overweight And Obese Subjects With Elevated Ldl-C, As This Population Is Characteristic Of Nonalcoholic Fatty Liver Disease (Nafld),&Rdquo; Said Melissa Palmer, Md, Chief Medical Officer Of Gannex, &Ldquo;The Data From This Study Offered Important Safety And Preliminary Efficacy Readouts That Enable Us To Advance This Clinical Program Into Patients With Nash.&Rdquo;With The Positive Clinical Results In Overweight And Obese Subjects For Asc41 And The Company'S Participation In Recent Sagimet'S Us$ 80 Million Crossover Financing With Global Premium Investors,&Rdquo; Said Dr. Jinzi J. Wu, Founder, Chairman And Ceo Of Ascletis, &Ldquo;We Are Moving Forward At Full Speed For Our Global Leading Nash Pipeline With Three Different Targets, Fasn, Thr-&Szlig; And Fxr.&Rdquo;
